Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Non-cash Items: 2017-2024

Historic Non-cash Items for Aclaris Therapeutics (ACRS) over the last 8 years, with Dec 2024 value amounting to $10.0 million.

  • Aclaris Therapeutics' Non-cash Items rose 7.83% to $12.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 7.83%. This contributed to the annual value of $10.0 million for FY2024, which is 71328.57% up from last year.
  • According to the latest figures from FY2024, Aclaris Therapeutics' Non-cash Items is $10.0 million, which was up 71,328.57% from $14,000 recorded in FY2023.
  • Over the past 5 years, Aclaris Therapeutics' Non-cash Items peaked at $15.3 million during FY2022, and registered a low of $14,000 during FY2023.
  • For the 3-year period, Aclaris Therapeutics' Non-cash Items averaged around $8.4 million, with its median value being $10.0 million (2024).
  • In the last 5 years, Aclaris Therapeutics' Non-cash Items slumped by 99.91% in 2023 and then spiked by 71,328.57% in 2024.
  • Yearly analysis of 5 years shows Aclaris Therapeutics' Non-cash Items stood at $4.9 million in 2020, then surged by 180.37% to $13.7 million in 2021, then grew by 11.51% to $15.3 million in 2022, then plummeted by 99.91% to $14,000 in 2023, then soared by 71,328.57% to $10.0 million in 2024.